Skip to main content
Erschienen in: CardioVascular and Interventional Radiology 2/2017

20.09.2016 | Letter to the Editor

Hepatic Arterial Therapy for First-Line Treatment of Unresectable Colorectal Liver Metastases: What We Know in the Wake of Two Recent Randomized Control Trials

verfasst von: Olaguoke Akinwande, Robert CG Martin

Erschienen in: CardioVascular and Interventional Radiology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Excerpt

The most common site of metastatic disease from colorectal cancer is the liver, and liver disease frequently dictates the prognosis. Therefore, it is sensible to be aggressive in treating colorectal liver metastases (CRLM). Surgical resection is the only chance of long-term disease control (5-year survival 25 to 58 %), but only about 25 % of the cases are deemed resectable at the time of presentation. For unresectable cases, systemic therapy is the standard-of-care for the initial first-line therapy. Unfortunately, those treated with systemic therapy will invariably develop dose-limiting toxicities or will progress leaving less responsive 2nd line and 3rd line options for disease control. HAT (chemoembolization or radioembolization) is commonly used in this clinical setting, and it has been shown to provide benefit in that regard [1]. HAT consists of the placement of a catheter into the hepatic artery through a femoral artery access site. Through the catheter, drug-eluting beads loaded with irinotecan (DEBIRI) or beads loaded with the radioactive yttrium 90 (90Y) isotope are delivered to the target liver lesions by taking advantage of differential perfusion (CRLMs and most liver tumors are preferentially perfused by the hepatic artery). As a result, HAT aggressively treats liver tumor burden with minimal collateral damage and systemic toxicity. …
Literatur
1.
Zurück zum Zitat Liapi E, Geschwind JF. Transcatheter and ablative therapeutic approaches for solid malignancies. J Clin Oncol. 2007;25:978–86.CrossRefPubMed Liapi E, Geschwind JF. Transcatheter and ablative therapeutic approaches for solid malignancies. J Clin Oncol. 2007;25:978–86.CrossRefPubMed
2.
Zurück zum Zitat Martin RC 2nd, Scoggins CR, Schreeder M, et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer. 2015;121:3649–58.CrossRefPubMed Martin RC 2nd, Scoggins CR, Schreeder M, et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer. 2015;121:3649–58.CrossRefPubMed
3.
Zurück zum Zitat Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25:1670–6.CrossRefPubMed Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25:1670–6.CrossRefPubMed
4.
Zurück zum Zitat Martin RC 2nd, Scoggins CR, Tomalty D, et al. Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. J Gastrointest Surg. 2012;16:1531–8.CrossRefPubMed Martin RC 2nd, Scoggins CR, Tomalty D, et al. Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. J Gastrointest Surg. 2012;16:1531–8.CrossRefPubMed
5.
Zurück zum Zitat Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol. 2007;25:5218–24.CrossRefPubMed Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol. 2007;25:5218–24.CrossRefPubMed
6.
Zurück zum Zitat van Hazel GA, Heinemann V, Sharma NK, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus Bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2016. doi:10.1200/JCO.2015.66.1181. van Hazel GA, Heinemann V, Sharma NK, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus Bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2016. doi:10.​1200/​JCO.​2015.​66.​1181.
7.
Zurück zum Zitat Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004;88:78–85.CrossRefPubMed Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004;88:78–85.CrossRefPubMed
Metadaten
Titel
Hepatic Arterial Therapy for First-Line Treatment of Unresectable Colorectal Liver Metastases: What We Know in the Wake of Two Recent Randomized Control Trials
verfasst von
Olaguoke Akinwande
Robert CG Martin
Publikationsdatum
20.09.2016
Verlag
Springer US
Erschienen in
CardioVascular and Interventional Radiology / Ausgabe 2/2017
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-016-1469-0

Weitere Artikel der Ausgabe 2/2017

CardioVascular and Interventional Radiology 2/2017 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.